Tuesday 28th February 2017

We are supporting Rare Disease Day

Read Article

Wednesday 22nd February 2017

Scleroderma & Raynaud’s UK online test helps over 3,000 people establish if they have Raynaud’s

Read Article

Wednesday 8th February 2017

Running and Raynaud's

How to look after yourself when running.

Read Article

Monday 9th January 2017

Raynaud's Awareness Month 2017

February 2017 was Raynaud's Awareness Month and SRUK supported it with raise your hands.

Read Article

Tuesday 3rd January 2017

Stem cells offer new hope for scleroderma

Dan Muscat, 49, developed systemic scleroderma in 2014, in which the skin all over his body began to harden and tighten due to the overproduction of collagen. An experimental stem-cell treatment has meant a "180-degree" turn in Dan's symptoms.

Read Article

Tuesday 3rd January 2017

Raynaud's and open water swimming

Raynaud’s attacks, usually triggered by the cold causing a lack of blood flow to the extremities, are often mild and manageable; however diving into cold water may cause problems.

Read Article

Tuesday 13th December 2016

UK Strategy for Rare Diseases

Read Article

Monday 28th November 2016

Get involved in Rare Diseases Day and help represent Scleroderma

SRUK will be supporting Rare Diseases Day February 2017.

Read Article

Monday 3rd October 2016

Scleroderma blog by Alison Juggler

Scleroderma is a rare disease that affects the immune system. Your body starts to attack healthy tissue and produce excess collagen, affecting the skin, joints, blood vessels, tendons and internal organs (eek!). The resulting scarring and stiffness varies in severity, but it can be disabling and even life-threatening when you have the most serious type of of scleroderma: systemic. Yep, that’s what my daughter

Read Article

Wednesday 28th September 2016

Nintedanib Receives Orphan Drug Designation for Systemic Sclerosis

The FDA has granted Orphan Drug Designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD). - See more at: http://www.pharmacytimes.com/product-news/nintedanib-receives-orphan-drug-designation-for-systemic-sclerosis#sthash.5ACj39Ga.dpuf

Read Article